
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Treatment of Clostridioides difficile: The Times They Are Changing</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Treatment of Clostridioides difficile: The Times They Are Changing</strong></summary>
            <div>
                <ul><li>Journal: Am J Gastroenterol</li><li>Publication Date: April 7, 2025</li><li>DOI: https://doi.org/10.14309/ajg.0000000000003445</li><li>Focus: Evolving treatment landscape for Clostridioides difficile infection (CDI), emphasizing new and changing therapeutic options.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What percentage of patients receiving standard-of-care antimicrobials for CDI experience a recurrence?</li><li>2. Which CDI treatment, once FDA-approved, was removed from the market on January 31, 2025?</li><li>3. What is the anticipated impact of fidaxomicin coming off patent on its accessibility and cost?</li><li>4. For severely immunocompromised patients with recurrent CDI, why are FDA-approved donor-derived microbiota therapies generally not recommended?</li><li>5. What specific challenge does the sunsetting of Openbiome pose for patients with severe or fulminant CDI?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Clostridioides difficile Infection (CDI) Overview</strong></summary>
            <div>
                <ul><li>Most common healthcare-associated infection in US.</li><li>Recurrence is a major challenge.</li><li>Treatment goals: treat active infection + prevent recurrences.</li></ul>
                
        <details>
            <summary><strong>Recurrence Rates</strong></summary>
            <div>
                <ul><li>≈25% of patients recur after standard antimicrobials.</li><li>Of those, ≈35% will subsequently recur.</li><li>Thereafter, ≈60% will recur, creating a challenging cycle.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Historical Advancements</strong></summary>
            <div>
                <ul><li>Last 20 years: research focused on ↓ recurrence.</li><li>Approaches: highly selective antimicrobials (e.g., fidaxomicin), toxin-targeting infusions (e.g., bezlotoxumab), fecal microbiota transplantation (FMT) for microbiota diversity restoration.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Key Treatment Modalities &amp; Changes</strong></summary>
            <div>
                <ul><li>Treatment options rapidly changing (2024-2025+).</li><li>Clinicians must understand available options + optimal usage.</li></ul>
                
        <details>
            <summary><strong>Fidaxomicin</strong></summary>
            <div>
                <ul><li>FDA approved: 2011; first next-gen therapeutic.</li><li>Mechanism: novel, highly selective therapy targeting C. difficile.</li><li>Benefit: limited collateral microbiome disruption → maintains colonization resistance → ↓ recurrence.</li></ul>
                
        <details>
            <summary><strong>Effectiveness</strong></summary>
            <div>
                <ul><li>Generational treatment w/ significantly ↓ recurrent rates vs. vancomycin.</li><li>Consistent superiority vs. vancomycin.</li><li>Metronidazole: remarkably ↓ efficacy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Current Status &amp; Future</strong></summary>
            <div>
                <ul><li>Preferred antimicrobial for initial + recurrent CDI.</li><li>High costs hampered widespread usage despite guideline inclusion.</li><li>Expected to come off patent → anticipated ↓ costs + ↑ availability → broader patient benefit.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Regimens</strong></summary>
            <div>
                <ul><li>Standard: 200 mg PO BID x 10 days.</li><li>EXTEND regimen: 200 mg PO BID x 5 days, then QOD for days 7–25 (total 20 doses).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Bezlotoxumab</strong></summary>
            <div>
                <ul><li>FDA approved: May 2016.</li><li>Mechanism: infusion targeting CDI toxins, given during standard antimicrobial therapy.</li><li>Benefit: associated w/ ↓ rates of recurrence.</li></ul>
                
        <details>
            <summary><strong>Target Population</strong></summary>
            <div>
                <ul><li>Essential addition for select patients.</li><li>Benefit in age ≥65, immunosuppressed, or severe CDI.</li><li>Added importance during COVID-19 pandemic due to FMT unavailability.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Availability Change</strong></summary>
            <div>
                <ul><li>Merck &amp; Co. ceased production/marketing.</li><li>Removed from market: January 31, 2025.</li><li>Impact: creates significant gap in treatment options, especially for severely immunocompromised (FMT not recommended for this cohort).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Fecal Microbiota Transplantation (FMT) &amp; Microbiota-Based Therapies</strong></summary>
            <div>
                <ul><li>FMT: safe + effective method to remarkably ↓ rCDI when administered following standard antimicrobial.</li><li>FDA approvals aimed to broaden clinician comfort + access.</li></ul>
                
        <details>
            <summary><strong>FDA Approved Products</strong></summary>
            <div>
                <ul><li>Fecal microbiota, live-jslm (RBL): broad consortium, enema-based formulation.</li><li>Fecal microbiota spores, live-brpk (VOS): narrow consortium of Firmicutes, encapsulated form.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Openbiome Changes</strong></summary>
            <div>
                <ul><li>Largest US stool bank.</li><li>September 2024: advised voluntary cessation of distributing treatments for rCDI prevention.</li><li>As of 12/31/24: no longer available generally, except for severe + fulminant disease.</li><li>Impact: conventional FMT will largely sunset, leaving a hole in treatment for fulminant CDI.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Role in Fulminant CDI</strong></summary>
            <div>
                <ul><li>No data for RBL or VOS in fulminant patient population.</li><li>Their role for fulminant disease is unclear.</li><li>Openbiome&#x27;s sunsetting narrows options for sickest patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Current Availability</strong></summary>
            <div>
                <ul><li>RBL + VOS: excellent options to prevent rCDI for other cohorts.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Approach to CDI Treatment in Evolving Landscape</strong></summary>
            <div>
                <ul><li>Need to understand best approach for patients given changing options.</li><li>Adapt to evolving options.</li></ul>
                
        <details>
            <summary><strong>First-Line Therapy</strong></summary>
            <div>
                <ul><li>If fidaxomicin costs significantly reduced (post-patent expiration):</li><li>Should be first-line option for both initial + recurrent disease, as per guidelines.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Add-on Therapies (Post-Antimicrobial)</strong></summary>
            <div>
                <ul><li>Losing bezlotoxumab is challenging.</li><li>FDA-approved donor-derived microbiota therapies (RBL, VOS) are available.</li></ul>
                
        <details>
            <summary><strong>Immunocompetent / Mildly Immunocompromised</strong></summary>
            <div>
                <ul><li>Patients at greatest risk for future recurrence (e.g., multiply recurrent CDI, concomitant IBD).</li><li>Previously considered for bezlotoxumab.</li><li>Now: should receive one of the FDA-approved microbiota-based therapeutics (RBL or VOS).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Severely Immunocompromised</strong></summary>
            <div>
                <ul><li>Not eligible for FDA-approved donor-derived microbiota therapies.</li><li>Need more creative antimicrobial usage or novel approaches.</li></ul>
                
        <details>
            <summary><strong>Vancomycin Tapers with Pulses</strong></summary>
            <div>
                <ul><li>Example: 125 mg PO QID x 14 days, then 125 mg PO BID x 7 days, then 125 mg PO QD x 7 days, then 125 mg PO QOD x 8 days, then 125 mg PO Q3D x 15 days (total 86 doses).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Fidaxomicin EXTEND Regimen</strong></summary>
            <div>
                <ul><li>200 mg PO BID x 5 days, followed by 1 tablet every other day for days 7–25.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Severe or Fulminant Disease (Post-Openbiome Sunset)</strong></summary>
            <div>
                <ul><li>Consider usage of unapproved FMT or RBL administration through colonoscopy.</li><li>No data for RBL/VOS in this population; VOS (capsule) cannot be administered via colonoscopy.</li></ul>
                
        <details>
            <summary><strong>Fischer&#x27;s Protocol (for RBL via colonoscopy)</strong></summary>
            <div>
                <ul><li>Administer every other to every third day until pseudomembranes disappear.</li><li>Consider repeat RBL or unapproved FMT treatment several weeks after hospital discharge.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Guidelines &amp; Practical Considerations</strong></summary>
            <div>
                <ul><li>All should consider following American Gastroenterological Association Guidelines.</li><li>Become more comfortable using RBL + VOS, even as early as first recurrence in high-risk patients.</li><li>Insurance challenges remain + will likely continue to evolve.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
